Welcome message

Dear Colleagues, Dear Friends,

On behalf of the Board of Directors and the Program Committee it is a great pleasure to invite you to the 2024 Insight Biennial Conference to be held in Barcelona at 19th – 22nd June 2024.

This conference, which focusses on the worldwide improvement of care of patients and families with any hereditary condition resulting in gastrointestinal tumors, is a great opportunity and challenge. We aim to make this a great scientific meeting that attracts clinical and research experts in the field, including PhD students and other early career scientists and physicians.

The Program Committee has been working hard to put together a vibrant and comprehensive program for the meeting securing the participation of internationally acknowledged invited experts to address hot topics on key areas in Fundamental, Translational and Clinical Science in sessions with invited speakers and the best peer-reviewed abstracts as oral communications. Workshops will allow lively debating. We will also have the opportunity to listen the voice of patients critical to adequately design our care and our research.

Selected topics include among others: Mutational signatures and somatic evolution in normal tissue; the use of artificial intelligence (AI) in Digital pathology and Endoscopies; and monogenetic defects and Polygenic Risk Scores. Regarding clinical science we will be addressing surgical challenges as well as controversies in surveillance and testing in pediatric and adult settings. Issues on colorectal, gynecological, gastric and biliopancreatic neoplasms will also be discussed. Also chemoprevention, vaccines and lifestyle modification will be tackled. Finally, we have joined forces with the European Society of Gastrointestinal Endoscopy to organize a pre-meeting educational event.

A scientific congress is not just a series of lectures or debates delivered from a podium. There is the social interaction, meeting old friends and making new acquaintances which may turn to become lifelong, discussing a project over a coffee, inviting colleagues to spend time in our unit. Especially for trainees, a congress represents the unique opportunity to meet renowned professionals and establish connections that can lead to new professional opportunities. In this regard, we have done our best to promote the active participation of the young people hoping to help providing effective enduring mentorship to the next generation of physicians, health professionals and scientists.

As Chairpersons of Insight we are very happy and honored to welcome all of you in Barcelona next June to share and learn the most up to date evidence in our specialty and to enjoy networking with your friends and colleagues.

Kind regards, also on behalf of the InSiGHT Scientific Committee
Conference directors

Meeting directors & core scientific committee

Prof. Dr. Nicoline Hoogerbrugge
MD, PhD, Internist-cancer geneticist. Radboud university medical center
Nijmegen, Netherlands

Dr. Gabriel Capellá
MD, PhD, Catalan Institute of Oncology (IDIBELL), Cancer geneticist
L’Hospitalet de Llobregat, Spain

Dr. Francesc Balaguer
MD, PhD, Gastroenterologist. Hospital Clinic
Barcelona, Spain

Prof. dr. Marjolijn Ligtenberg
PhD, Molecular geneticist. Radboud university medical center
Nijmegen, Netherlands

Dr. Joanne de Hullu
MD, PhD, Gynecologist. Radboud university medical center
Nijmegen, Netherlands

Dr. Marta Pineda
PhD, Biochemist. Catalan Institute of Oncology (ICO) & Bellvitge Biomedical Research Institute (IDIBELL)
L’Hospitalet de Llobregat, Spain

Dr. Leticia Moreira
MD, PhD, Gastroenterologist. Hospital Clinic
Barcelona, Spain

Dr. Joan Brunet
MD, PhD, Medical Oncologist. Catalan Institute of Oncology - IDIBGI
Girona, Spain

Dr. Chella van der Post
MD, PhD, Pathologist. Radboud university medical center
Nijmegen, Netherlands

Dr. Laura Valle
PhD, Biochemist. Bellvitge Biomedical Research Institute (IDIBELL)
L’Hospitalet de Llobregat, Spain

Dr. Maria Pellisé
MD, PhD, Gastroenterologist. Hospital Clinic
Barcelona, Spain

Dr. Miriam Cuatrecasas
MD, PhD, Pathologist. Hospital Clinic
Barcelona, Spain

Dr. Judith Balmaña
MD, PhD, Medical Oncologist. Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Dr. Tanya Bisseling
MD, PhD, Gastroenterologist. Radboud university medical center
Nijmegen, Netherlands
Pre-InSiGHT Programme for Patients

TUESDAY, JUNE 18TH

Virtual session

Organised in collaboration with ERN GENTURIS
Pre-InSiGHT Programme for Patients

TUESDAY, JUNE 18TH

Virtual session

19:00 - 21:00  **Pre-InSiGHT meeting for patients and patient representatives with Lynch syndrome or polyposis**  
*Chairs:*  
Nicoline Hoogerbrugge, Radboud university medical center, Nijmegen, The Netherlands  
Gabriel Capellá, Catalan Institute of Oncology (ICO) & Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Spain  
Organised in collaboration with ERN GENTURIS

---

19:00 - 19:20  **What do you need to know about colonoscopy?**  
Francesc Balaguer, Hospital Clinic Barcelona, Spain

19:20 - 19:40  **Different Lynch genes have different hereditary risks: PMS2 is the odd out**  
Brandie Leach, Hereditary Cancer Medical Affairs, Exact Sciences, Cleveland, Ohio, USA

19:40 - 20:00  **Life after colectomy**  
Toni T. Seppälä, Tampere University Hospital, Tampere University and TAYS Cancer Centre, Finland

20:00 - 20:30  **Promising news: Immune therapy in cancer treatment of patients with Lynch syndrome**  
Dr. Judith Balmaña, Vall d’Hebron, Institute of Oncology (VHIO), Barcelona, Spain

20:30 - 21:00  **Questions from the audience**

21:00  **Closing remarks**
InSiGHT-ClinGen
Polyposis-CRC VCEP Meeting

WEDNESDAY, JUNE 19TH
## InSiGHT-ClinGen Polyposis-CRC VCEP Meeting

**WEDNESDAY, JUNE 19TH**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45 - 08:00</td>
<td><strong>Check-in, Coffee and Light Breakfast</strong></td>
</tr>
<tr>
<td>08:00 - 08:15</td>
<td><strong>Introduction, Overview</strong></td>
</tr>
<tr>
<td>08:15 - 08:45</td>
<td><strong>MMR subVCEP</strong></td>
</tr>
<tr>
<td></td>
<td>- History in InSiGHT, transition to InSiGHT ClinGen Expert Panel</td>
</tr>
<tr>
<td></td>
<td>- New MMR-Specific ACMG rules</td>
</tr>
<tr>
<td></td>
<td>- Future</td>
</tr>
<tr>
<td>09:25 - 10:05</td>
<td><strong>MUTYH subVCEP</strong></td>
</tr>
<tr>
<td></td>
<td>- Process</td>
</tr>
<tr>
<td></td>
<td>- New MUTYH-Specific Classification Rules</td>
</tr>
<tr>
<td></td>
<td>- Pilot Study</td>
</tr>
<tr>
<td></td>
<td>- Future</td>
</tr>
<tr>
<td>10:05 - 10:30</td>
<td><strong>Break, Coffee and Light Breakfast</strong></td>
</tr>
<tr>
<td>10:30 - 10:55</td>
<td><strong>Hampartomatous Polyp subVCEP SMAD4/BMPR1A/STK11</strong></td>
</tr>
<tr>
<td></td>
<td>- Process</td>
</tr>
<tr>
<td></td>
<td>- HHT-Polyposis Joint effort</td>
</tr>
<tr>
<td></td>
<td>- Future</td>
</tr>
<tr>
<td>10:55 - 11:20</td>
<td><strong>POLD1/POLE subVCEP</strong></td>
</tr>
<tr>
<td>11:20 - 11:50</td>
<td><strong>U24 Grant Renewal Aims</strong></td>
</tr>
<tr>
<td>11:50 - 01:00</td>
<td><strong>Lunch</strong></td>
</tr>
</tbody>
</table>

This session is directed toward participants in the InSiGHT-ClinGen Hereditary CRC-Polyposis Variant Curation Expert Panel. If you would like to attend, kindly send an email to congresos@tacticsmd.net.
Pre-InSiGHT Programme

WEDNESDAY, JUNE 19TH
Pre-InSiGHT Programme

WEDNESDAY, JUNE 19TH

08:25 - 12:20 ESGE/ESDO postgraduate course:
“Advances in GI endoscopy and immunotherapy in the management of hereditary GI syndromes”

Chairs:
Ian Gralnek, Institute of Gastroenterology and Hepatology, Emek Medical Center, Afula, Israel
Thomas Seufferlein, Ulm University, Germany

08:00 - 08:30 Registration
08:25 - 08:30 Welcome message

08:30 - 09:30 SESSION 1:
Tips and Tricks for colonoscopy in high-risk conditions

Chairs:
Ian Gralnek, Institute of Gastroenterology and Hepatology, Emek Medical Center, Afula, Israel
Francesc Balaguer, Hospital Clinic, Barcelona, Spain

- Surveillance of the colon in Lynch Syndrome: Tips and tricks
  Maria Pellisé, Hospital Clinic, Barcelona, Spain
- Surveillance of the pouch/rectum in FAP: Tips and tricks
  Andrew Latchford, St Mark’s Hospital, London North West University Healthcare NHS Trust, London, United Kingdom
- Management of SPS: How to diagnose and treat SSLs
  Evelien Dekker, Amsterdam University Medical Centers, The Netherlands
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
<th>Presenters</th>
</tr>
</thead>
</table>
| 09:30 - 10:30 | **SESSION 2:** Tips and tricks for upper endoscopy in high-risk conditions | **Chairs:** Maria Pellisé, Hospital Clinic, Barcelona, Spain Andrew Latchford, St Mark's Hospital, London North West University Healthcare NHS Trust, London, United Kingdom | Prevention of gastric cancer: Tips and tricks for a high-quality upper GI endoscopy Mário Dinis-Ribeiro, Instituto Português de Oncologia, Porto, Portugal  
Prevention of gastric cancer in FAP Arthur Aelvoet, ANIOS MDL, Amsterdam, The Netherlands  
Managing CDH1/CTNNA1 patients Tanya Bisseling, Radboud university medical center, Nijmegen, The Netherlands |
| 10:30 - 11:00 | **Coffee Break**                             |                                                                     |                                                                                                     |
| 11:00 - 11:40 | **SESSION 3:** Surveillance of the duodenum in high-risk conditions | **Chairs:** Evelien Dekker, Amsterdam University Medical Centers, The Netherlands Tanya Bisseling, Radboud university medical center, Nijmegen, The Netherlands | How to deal with intestinal polyps in Peutz Jeghers? Begoña González, Teknon Medicaal Center, Barcelona, Spain  
Management of duodenal polyposis in FAP John Gåsdal Karstensen, University of Copenhagen, Denmark |
| 11:40 - 12:20 | **SESSION 4:** New advances in immunotherapy in GI cancers | **Chairs:** Thomas Seufferlein, Ulm University, Germany | Immunotherapy in colorectal cancer Eric Van Cutsem, University Hospital Gasthuisberg/Leuven, Belgium  
Immunotherapy in upper GI cancer Thomas Seufferlein, Ulm University, Germany |
Scientific programme of InSiGHT Conference

WEDNESDAY, JUNE 19TH

THURSDAY, JUNE 20TH

FRIDAY, JUNE 21ST

SATURDAY, JUNE 22ND
Scientific programme of InSiGHT Conference

**WEDNESDAY, JUNE 19TH**

12:00 - 13:00  **Registration**

13:00 - 13:20  **Welcome and announcements**

_Nicoline Hoogerbrugge_, Radboud university medical center, Nijmegen, The Netherlands
_Gabriel Capellá_, Catalan Institute of Oncology (ICO) & Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain

13:20 - 15:25  **SESSION 1 – TRANSLATIONAL SCIENCE**

_Chairs:_
_Chella van der Post_, Radboud university medical center, Nijmegen, Netherlands
_Maria Pellisé_, Hospital Clinic Barcelona, Spain

13:20 - 13:45  **Use of AI in Endoscopies**

_Robert Hüneburg_, Bonn University Hospital, Bonn, Germany

13:45 - 14:10  **Use of AI in colorectal cancer: its application to GI hereditary tumors**

_Francesco Ciompi_, Radboud university medical center, Nijmegen, The Netherlands

14:10 - 14:55  **Debate: Strategies to find all patients with hereditary cancer**

_Stefan Aretz_, University Hospital Bonn, Bonn, Germany
_Judith Balmaña_, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
14:55 - 15:25

**Abstract Presentations 1**

14:55 - 15:05
Predictors of invasive signet ring cell carcinoma in CDH1 carriers – results from the multicenter Study of CDH1 Outcomes & Surveillance
Ophir Gilad, University of Chicago, Illinois, United States

15:05 - 15:15
Familial serrated polyposis syndrome in the genetics of colonic polyposis study
Daniel Buckmann, University of Pittsburgh, Pennsylvania, United States

15:15 - 15:25
Machine learning-based endoscopic classification for superficial mucosal lesions in hereditary diffuse gastric cancer
Leanne Wu, Cambridge University, United Kingdom

15:25 - 15:35
Testing colonic ganglioneuromas as a clue to the diagnosis of PTEN hamartoma tumor syndrome
Chella Van der Post, Radboud university medical center, Nijmegen, The Netherlands

15:35 - 15:45
Can genomic features of pre-malignant adenomas be used to identify biallelic MUTYH and NTHL1 carriers?
Romy Walker, University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Melbourne, Australia

15:45 - 15:55
Multicentre approach to improve the identification and management of CMMRD patients in Spain
Fátima Marín, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain

15:25 - 15:55
☕ Coffee Break
SESSION 2 – TRANSLATIONAL SCIENCE

Chairs:
Marta Pineda, Catalan Institute of Oncology (ICO) & Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Spain
Elke Holinski-Feder, München Ludwig-Maximilians-Universität, Germany

15:55 - 16:20
Microbiome and (risk of) hereditary GE cancer
Annemarie Boleij, Radboud university medical center, Nijmegen, The Netherlands

16:20 - 17:50
Abstract Presentations 2

16:20 - 16:30
HLA Type as a possible modulator of cancer risk in Lynch syndrome: first data from the INDICATE Network
Lena Bohaumilitzky, University Hospital Heidelberg, Germany

16:30 - 16:40
A faecal microbial signature to optimise colorectal cancer surveillance in Lynch syndrome
Sandra Taboada-López, GoodGut SL, Girona, Spain

16:40 - 16:50
Germline results following comprehensive genomic tumour sequencing of 1070 gynaecological cancers
Arianna Panfili, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

16:50 - 17:00
IL-17A-Producing NKp44(-)ILC3s may promote duodenal adenoma formation in familial adenomatous polyposis
Jacob Nattermann, University Hospital Bonn, Germany
Scientific programme of InSiGHT Conference

17:00 - 17:10
**Characterization of the mutational landscape of colorectal tumors from individuals with adenomatous or serrated polyposis**
*Anna Sommer,* University Hospital Bonn, Germany

17:10 - 17:20
**Lynch syndrome-related neoantigens prediction and validation for a dendritic-cell based cancer prevention vaccine**
*Cristina Bayó Llorens,* Hospital Clinic Barcelona, Spain

17:20 - 17:30
**Profiling germline and somatic mutations in consecutive early onset colorectal cancer cases in a European population**
*Penelope Edwards,* The Centre for Familial Intestinal Cancer, St Mark’s Hospital, London Northwest Healthcare Trust, United Kingdom

17:30 - 17:40
**Prevalence of DNA mismatch repair (MMR) gene mosaicism and specific intronic pathogenic variants in people with MMR-deficient cancers**
*Romy Walker,* University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Melbourne, Australia

17:40 - 17:50
**Gastric epithelium and patient-derived gastric organoids from BRCA1/2 carriers harbor increased proliferation and DNA damage**
*Bryson Katona,* University of Pennsylvania Perelman School of Medicine, PA, United States

17:50 - 18:00
**Adjourning**

19:00
**Welcome Reception**

*Location:* Conference Venue
SESSION 3 – FUNDAMENTAL SCIENCE

08:30 - 08:55
New genetic aspects of Lynch syndrome
Marjolijn Ligtenberg, Radboud university medical center, Nijmegen, The Netherlands

08:55 - 09:20
New genes for polyposis
Laura Valle, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Spain

09:20 - 09:50
Abstract Presentations 3

09:20 - 09:30
Establishing a deep mutational scan for MSH6 missense variant classification
Anthony Scott, University of Michigan, Ann Arbor, MI, United States

09:30 - 09:40
The immune profile of Lynch syndrome-associated colorectal adenomas pinpoints the main determinants of immune activation
Lena Bohaumilitzky, Institute of Pathology, University Hospital Heidelberg, Germany

09:40 - 09:50
Diagnostic challenges of MLH1 constitutional epimutations involved in Lynch syndrome
Julie Leclerc, Jeanne de Flandre Hospital, Lille University Hospital, France
09:50 - 09:53
The germline POLD1 c.1420C>A p.(Leu474Ile) variant segregates with endometrial cancer and colonic adenomas demonstrating hypermutation and defective POLD1 mutational signatures
Khalid Mahmood, The University of Melbourne, Parkville, Victoria, Australia

09:53 - 09:56
Adenomatous polyps of germline pathogenic PMS2 mutation carriers: preliminary epidemiological and histopathological report from the LYNCH-GPS study
Katarina Andini, University Medical Centre Groningen, The Netherlands

09:56 - 09:59
Diagnostic yield and characterization of endoscopic surveillance in CDH1 pathogenic variant carriers in Spain
Joaquin Castillo, Hospital Clínic Barcelona, Spain

09:59 - 10:02
Mesalamine for colorectal cancer prevention program in Lynch Syndrome (MesaCAPP)
Ann-Sofie Backman, Karolinska Institutet, Huddinge, Stockholm, Sweden

10:02 - 10:05
Birth cohort effect on age of colorectal cancer onset in Lynch syndrome
Ophir Gilad, University of Chicago, Illinois, United States

10:05 - 11:05
Coffee Break + Poster session A
Scientific programme of InSiGHT Conference

11:05 - 12:25  SESSION 4 – FUNDAMENTAL SCIENCE

Chairs:
Maurizio Genuardi, University of Florence, Italy
Beneditto Rossi, Hospital Sirio Libanes, São Paulo, Brazil

11:05 - 11:30
Mutational signatures (somatic evolution in normal tissue)
Gene Koh, University of Cambridge, Cambridge, United Kingdom

11:30 - 11:55
Updated international guidelines on hereditary diffuse gastric cancer, hot news from Porto
Carla Oliveira, Ipatimup, Porto, Portugal

11:55 - 12:25
• Abstract Presentations 4

11:55 - 12:05
Genomic features of post-colonoscopy colorectal cancers in people with Lynch syndrome
Daniel Buckanan, Victorian Comprehensive Cancer Centre, The University of Melbourne, Parkville, Victoria, Australia

12:05 - 12:15
CaptureRNA-seq as a supplement to DNA germline testing to increase the diagnostic yield of hereditary tumor syndromes
Megan Hitchins, Cedars-Sinai Medical Center, Los Angeles, CA

12:15 - 12:25
The exome-wide genomic profile of Lynch syndrome-related colorectal cancers differs by affected gene: implications for determining pathways of tumourigenesis
Peter Georgeson, Victorian Comprehensive Cancer Centre, The University of Melbourne, Parkville, Victoria, Australia
Scientific programme of InSiGHT Conference

12:25 - 13:10
- Debate: Surveillance in moderate risk genes
  - Sonia Kupfer, University of Chicago, Chicago, United States
  - Andrew Latchford, St Mark’s Hospital, London North West University Healthcare NHS Trust, London, United Kingdom

13:10 - 14:10
- Lunch break

14:10 - 16:00

SESSION 5 – CLINICAL SCIENCE

Chairs:
- Evelien Dekker, Amsterdam University Medical Centers, The Netherlands
- Peter P. Stanich, The Ohio State University, Wexner Medical Center Columbus, United States

14:10 - 14:35
- Endoscopic surveillance in hereditary GI syndromes
  - Francesc Balaguer, Hospital Clínic Barcelona, Spain

14:35 - 15:00
- Surveillance in children with FAP
  - Warren Hyer, St Marks Hospital & Chelsea and Westminster Hospital, London, United Kingdom

15:00 - 16:00

- Abstract Presentations 5
  - 15:00 - 15:10
    - Pancreatic cancer is more common than melanoma in non-white CDKN2A positive individuals
    - Colin Young, Ambry Genetics, Aliso Viejo, California, United States
  - 15:10 - 15:20
    - Lynch Syndrome (LS) patients with inflammatory bowel disease (IBD) have significantly higher intestinal neoplasia risk than LS patients without IBD
    - Swati G. Patel, University of Colorado – Anschutz School of Medicine, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado, United States
15:20 - 15:30  
**Early Onset colorectal mortality trends in Argentina, 1997-2020. Is it time to reduce the age of screening in average-risk adults?**  
First report in Latin America  
Marina Antelo, SCo, UNLa, CONICET, Buenos Aires, Argentina

15:30 - 15:40  
**Detection of early gastric cancer during endoscopic surveillance in CDH1 and CTNNA1 pathogenic variant carriers: higher yield with targeted than with random biopsies**  
Tanya Bisseling, Radboud university medical centre, Nijmegen, the Netherlands

15:40 - 15:50  
**Psychosocial distress and quality of life in families with a germline CDKN2A pathogenic variant**  
Monique van Leerdam, Netherlands Cancer Institute, Amsterdam, The Netherlands

15:50 - 16:00  
**Variable cancer penetrance among CTNNA1 loss-of-function carriers: Initial results from the CTNNA1 Familial Expansion (CAFÉ) Study**  
Bryson W. Katona, Perelman Center for Advanced Medicine, Philadelphia, PA, United States

16:00 - 16:30  
☕ **Coffee Break**

16:30 - 17:15  
**Debate: New-born testing on hereditary cancer genes**  
Héctor Salvador, Hospital Sant Joan de Déu, Barcelona, Spain  
Ingrid Winship, University of Melbourne & Royal Melbourne Hospital, Melbourne, Australia
17:15 - 17:25
Digestive burden of patients with constitutional mismatch repair deficiency syndrome, diagnostic pitfalls, and experience of immunotherapy: a report from the C4CMMRD database
Chrystelle Colas, Curie Institute, Paris, France

17:25 - 17:35
Gastric and duodenal cancer in individuals with Lynch syndrome: a nationwide cohort study
TBC

17:35 - 17:45
Familial uveal melanoma and other tumours in 25 families with monoallelic germline MBD4 variants.
Marie-Charlotte Villy, Curie Institute, Paris, France

17:45 - 17:55
An evaluation of user experiences, perceptions and attitudes towards Faecal Immunochemical Testing (FIT) for risk-stratified colonoscopy in Lynch syndrome patients
Annie Lincoln, Comprehensive Cancer Centre, King's College London, London, United Kingdom

17:55 - 18:05
Systematic review of the phenotypic cancer spectrum in NTHL1-associated tumour syndrome emphasizes the need to identify more families to assess cancer risks
Weilun Gao, Royal Melbourne Hospital & University of Melbourne, Australia

18:05 - 18:15
Differences in adenoma and post-colonoscopy colorectal cancer detection between Lynch syndrome carriers with and without a previous colorectal cancer
Ariadna Sánchez, Hospital Clinic Barcelona, Spain
Scientific programme of InSiGHT Conference

18:15 - 18:20  Adjourning

20:00  Get Together

Venue: Casa de Les Punxes
Address: Av. Diagonal, 420, L’Eixample, 08037 Barcelona
(Limited Places - Registration Required)

FRIDAY, JUNE 21ST

08:30 - 10:05  SESSION 6 – CLINICAL SCIENCE

Chairs:
Bryson W. Katona, Perelman Center for Advanced Medicine, Philadelphia, PA, United States
Mathew Kalady, The Ohio State University, Comprehensive Cancer Center, Columbus, OH, United States

08:30 - 08:55
Surgery in Lynch syndrome and polyposis
Gabriela Mösllein, Academic Hospital of the University of Düsseldorf, Duisburg, Germany

08:55 - 09:20
Recent advances in Immunotherapy for GI and gynecological tumors
Iosune Baraibar, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
09:20 - 09:30  
Yield of multigene panel germline genetic testing among those with advanced colorectal adenomas  
Swati G. Patel, University of Colorado Anschutz School of Medicine, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado, United States

09:30 - 09:40  
Can butyrate prevent colon cancer? The AUSFAP study: A randomised, crossover clinical trial  
Finlay Macrae, The Royal Melbourne Hospital, Melbourne, Australia

09:40 - 09:50  
Cancer risks associated with germline pathogenic variants in MLH1, MSH2, MSH6, PMS2, and EPCAM genes  
Christine Drogan, University of Chicago, IL, United States

09:50 - 09:53  
Long read sequencing elucidates complex germline variants in individuals undergoing hereditary gastrointestinal cancer testing  
Sami Belhadj, Enterprise, Aliso Viejo, California, CA, United States

09:53 - 09:56  
Dietary habits of patients with or without hereditary cancer syndromes- A cross sectional cohort study  
Hitasha Mittal, Università Vita Salute San Raffaele, Milano, Italy

09:56 - 09:59  
A prospective analysis identified mismatch repair genes as candidate predisposing genes for uveal melanoma  
Anaïs Le Ven, PSL Research University, Paris, France
Scientific programme of InSiGHT Conference

09:59 - 10:02
Evaluation of upper gastrointestinal tract surveillance in individuals with Lynch Syndrome (EARLY) - An international registry
Tim Marwitz, University Hospital Bonn, National Center for Hereditary Tumor Syndromes, Bonn, Germany.

10:02 - 10:05
Optimizing POLE and POLD1 variant interpretation: gene-specific classification guidelines and in vitro system for functional assessment
Julen Viana-Errasti, Catalan Institute of Oncology (ICO) & Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain

10:05 - 11:05  ☕ Coffee Break + Poster session B

11:05 - 13:15  SESSION 7 – CLINICAL SCIENCE

Chairs:
Leticia Moreira, Hospital Clinic Barcelona, Spain
Rodrigo Jover, Hospital General Universitario Dr. Balmis, Alicante

11:05 - 11:30
Pancreas surveillance in high-risk individuals
Diane Simeone, NYU Pancreatic Cancer Center, New York, United States

11:30 - 12:30
● Abstract Presentations 8

11:30 - 11:40
Objective and subjective life expectancy in Lynch syndrome
Monique van Leerdam, Netherlands Cancer Institute, Amsterdam, The Netherlands

11:40 - 11:50
Racial and ethnic patterns of variants of uncertain significance (VUS) among patients with early-onset colorectal cancer
Andreana N. Holowatyj, Vanderbilt University Medical Center, Nashville, TN, United States
Scientific programme of InSiGHT Conference

11:50 - 12:00
**Ileocecal intubation in Lynch syndrome patients – go all the way!**
*Katrin van Beekum*, University Hospital Bonn, Germany

12:00 - 12:10
**An Aspirin a day? The (still) secret weapon against Colorectal Cancer in Lynch Syndrome**
*Rebecca Tuckey*, Te Whatu Ora – Health New Zealand Waitaha Canterbury, New Zealand

12:10 - 12:20
**Colorectal adenoma and cancer incidences in path_MMR carriers undergoing surveillance colonoscopy**
*Pål Møller*, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Norway

12:20 - 12:30
**Early onset colon and rectal cancer mortality in Lynch syndromes carriers subjected to surveillance colonoscopy**
*Pål Møller*, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Norway

12:30 - 13:15
**Debate: Early onset pancreatic cancer**
- Toni T. Seppälä, Tampere University Hospital, Tampere University and TAYS Cancer Centre, Finland
- Bryson Katona, University of Pennsylvania Perelman School of Medicine, PA, United States

13:15 - 14:15
**Lunch break**
Scientific programme of InSiGHT Conference

14:15 - 16:05  SESSION 8 – CLINICAL SCIENCE

Chairs:
Joan Brunet, Catalan Institute of Oncology, Girona Biomedical Research Institute (IDIBGI), Girona, Spain
Stefan Aretz, University Hospital Bonn, Bonn, Germany

14:15 - 14:40
Endometrial cancer in hereditary cancer syndromes
Emma J. Crosbie, St Mary's Hospital, Manchester, United Kingdom

14:40 - 15:05
Ovarian cancer in hereditary cancer syndromes
Neil Ryan, St Mary's Hospital, Manchester, United Kingdom

15:05 - 16:05
• Abstract Presentations 9

15:05 - 15:15
Recruiting Lynch Syndrome Patients for clinical research via social media improves participant diversity
Swati G. Patel, University of Colorado Anschutz School of Medicine, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado, United States

15:15 - 15:25
Development of abdominal desmoid tumours after colectomy and ileorectal anastomosis versus proctocolectomy and ileal pouch-anal anastomosis in familial adenomatous polyposis
Arthur Aelvoet, Amsterdam UMC, The Netherlands

15:25 - 15:35
Outcomes of Lynch syndrome endometrial cancer surveillance in a nation-wide cohort
Lotte van Leeuwen, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

15:35 - 15:45
Employing innovation to enhance the safety and reliability of restorative prophylactic surgical techniques for patients with familial adenomatous polyposis at a national referral centre
Bruno A. Alves Martins, St Mark's Hospital, London North West University Healthcare NHS Trust, London, United Kingdom
15:45 - 15:55
Risk of cancer and secondary surgery following colectomy with ileorectal anastomosis and proctocolectomy with ileal pouch-anal anastomosis in familial adenomatous polyposis.
Hicham Bouchiba, Amsterdam UMC, University of Amsterdam Cancer Center, The Netherlands

15:55 - 16:05
The new National english bowel cancer screening programme for Lynch syndrome colonoscopic Surveillance
Kevin Monahan, St Mark's Hospital, London North West University Healthcare NHS Trust, London, United Kingdom

16:05 - 16:35
Coffee Break

16:35 - 17:20
Debate: Strategies on endometrial and ovarian cancer in Lynch syndrome
Joanne A. de Hullu, Radboud university medical center, Nijmegen, The Netherlands
Anne van Altena, Radboud university medical center, Nijmegen, The Netherlands

17:20 - 18:20
Abstract Presentations 10

17:20 - 17:30
Optimizing mainstreaming of genetic testing in parallel with ovarian and endometrial cancer tumor testing: how do we maximize our impact?
Ying Liu, Memorial Sloan Kettering Cancer Center, New York, NY, United States

17:30 - 17:40
Cancer risk in hamatomatous polyposis syndromes: a focus on juvenile polyposis and Peutz-Jeghers
Emanuele Damiano Luca Urso, University of Padua, Italy
17:40 - 17:50  
The yield of artificial intelligence (GI genius) in Lynch syndrome – A randomized tandem-colonoscopy trial  
Ido Laish, Sheba Medical Center, Israel

17:50 - 18:00  
Specifications to the ACMG/AMP criteria enhance the classification of MMR variants  
John Paul Plazzer, Royal Melbourne Hospital, Parkville, Australia,

18:00 - 18:10  
The role of genotoxic gut bacteria in CRC tumourigenesis in Lynch syndrome  
Yen Lin Chu, Victorian Comprehensive Cancer Centre, The University of Melbourne, Parkville, Victoria, Australia

18:10 - 18:20  
Evaluating different testing approaches for identifying APC mosaicism in unexplained adenomatous polyposis: paving the way for the new susceptibility gene discovery  
Eric Joo, The University of Melbourne, Parkville, Australia

18:20 - 18:25  
Adjourning

18:30  
InSiGHT Business Meeting  
(Only for members)

20:00  
Congress Dinner  
Venue: Terraza Miramar  
Address: Plaça de l’Armada, s/n, Montjuïc, Sants-Montjuïc, 08038 Barcelona  
(Limited Seats - Registration Required)
08:30 - 10:20  SESSION 9 – CLINICAL SCIENCE

Chairs:
Monique van Leerdam, Netherlands Cancer Institute, Amsterdam, The Netherlands
Sue Clark, St Mark’s Hospital, Harrow, United Kingdom

08:30 - 08:55
Lifestyle and risk of hereditary cancer
Aung Ko Win, University of Melbourne Centre for Cancer Research, Melbourne, Australia

08:55 - 09:20
Surveillance frequency in familial colorectal cancer
Veerle Coupe, VU Medical Centre, Amsterdam, The Netherlands

09:20 - 10:20
• Abstract Presentations 11

09:20 - 09:30
Prevalence of pathogenic genetic variants in gastric cancer patients ascertained through multigene panel testing
Ophir Gilad, University of Chicago, Chicago, Illinois, United States

09:30 - 09:40
Discovery of recessive effect of human polymerase delta proofreading deficiency through mutational analysis of POLD1-mutated normal and cancer cells
Laura Valle, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain

09:40 - 09:50
Interrogating the landscape of immunogenic frameshift mutations in patients with Lynch syndrome and immune suppression programs supporting colorectal cancer development
Aimee Lucas, Icahn School of Medicine at Mount Sinai, New York, NY, United States
Scientific programme of InSiGHT Conference

09:50 - 10:00
Open-source bioinformatic pipeline to improve PMS2 genetic testing using short-read NGS data
Elisabeth Munté, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Spain

10:00 - 10:10
Germline variants in DNA interstrand-cross link repair genes may contribute to increased susceptibility for serrated polyposis in particular with proximal/whole colon localization of polyps, with implications for clinical management and therapeutics
Patrícia Silva, Istituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal

10:10 - 10:20
KRAS-G12C: a neglected biomarker for identifying MUTYH-associated polyposis patients
Giovana Torrezan, C.Camargo Cancer Center, São Paulo, Brazil

10:20 - 10:50  ☕ Coffee Break

10:50 - 12:25  SESSION 10 – CLINICAL SCIENCE

Chairs:
Allan Spigelman, University of New South Wales, Sydney
Tanya Bisseling, Radboud university medical center, Nijmegen, The Netherlands

10:50 - 11:15
Vaccines for Lynch syndrome
Eduardo Vilar, The University of Texas MD Anderson Cancer Center Houston, United States
11:15 - 11:40
Chemoprevention of hereditary GI cancer
John Burn, Professor of Clinical Genetics, Cancer Prevention, Newcastle University, Newcastle, United Kingdom

11:40 - 12:25
Debate: East versus West in colorectal cancer management
Joanne Ngeow, Cancer Genetics Service, National Cancer Centre Singapore
Finlay Macrae, The Royal Melbourne Hospital, Melbourne, Australia

12:25 - 13:25
Best Oral Communications

12:25 - 12:35
Preventing Cancer in Lynch Syndrome: Vaccination with mutation-derived neoantigen-loaded dendritic cells eliminates precancerous cells
Asima Abidi, Radboud university medical center, Nijmegen, The Netherlands

12:35 - 12:45
Homopolymer switches mediate adaptive mutability in mismatch repair-deficient colorectal cancer
Marnix Jansen, CL Cancer Institute, University College London, London, United Kingdom

12:45 - 12:55
Development and validation of a MIRNA-Based signature, Powered by machine learning, for predicting 10-year recurrence-free and overall survival after curative-intent treatment in early-onset colorectal cancer
Alessandro Mannucci, Beckman Research Institute of City of Hope, Monrovia, CA, United States
Scientific programme of InSiGHT Conference

12:55 - 13:05
**Colorectal carcinomas from path_MSH6 carriers display a lower degree and/or later onset of microsatellite instability and evoke weaker immune responses**
Noah Cornelis Helderman, Leiden University Medical Center, Leiden, The Netherlands

13:05 - 13:15
**Phase IIA trial of encapsulated rapamycin (ERAPA) in patients with familial adenomatous polyposis to reduce intestinal polyp burden: 6 month interim results**
Carol Burke, Cleveland Clinic, Cleveland, OH, United States

13:15 - 13:25
**Estimating cancer risk in carriers of Lynch syndrome variants in UK Biobank**
Albert Tenesa, The University of Edinburgh

13:25 - 13:40  **Concluding remarks**
Nicoline Hoogerbrugge, Radboud university medical center, Nijmegen, The Netherlands
Gabriel Capellá, Catalan Institute of Oncology (ICO) & Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain
Venue and main contact details

Venue

Auditorium & Convention Centre - AXA
Av. Diagonal, 547, Les Corts,
08029 Barcelona
+34 932 90 11 02

How to get there by public transport:
By underground:
L3, Maria Cristina station
By tram:
Line T3
By bus:
Lines 7, 33, 34, 63, 67, 68, 78, N12

Main contact details

Technical secretariat
General Information
Registration – Exhibition – Sponsorship

Tactics MD
Passatge Batlló 15, 08036 Barcelona
www.tacticsmd.net
+34 93 451 17 24

Ms. Laura Bravo
laura.bravo@tacticsmd.net

Ms. Raquel Gámez
raquel.gamez@tacticsmd.net

Insight headquarters

The International Society for Gastrointestinal Hereditary Tumours (InSiGHT)
The St Mark's Centre for Familial Intestinal Cancer, St Mark's Hospital, Central Middlesex Hospital Site. Acton Lane, London NW10 7NS, UK.

admin@insight-group.org
General information

Registration fees

<table>
<thead>
<tr>
<th></th>
<th>Early Bird (Until April 1st)</th>
<th>Regular (From April 2nd to June 19th)</th>
<th>Onsite</th>
</tr>
</thead>
<tbody>
<tr>
<td>InSiGHT Member Nurses, Genetic Counsellors, Students/Residents, Trainee*</td>
<td>325.00 €</td>
<td>500.00 €</td>
<td>600.00 €</td>
</tr>
<tr>
<td>InSiGHT Non Member - Nurses, Genetic Counsellors, Students/Residents, Trainee*</td>
<td>500.00 €</td>
<td>600.00 €</td>
<td>700.00 €</td>
</tr>
<tr>
<td>InSiGHT Member MD</td>
<td>600.00 €</td>
<td>700.00 €</td>
<td>800.00 €</td>
</tr>
<tr>
<td>InSiGHT Non Member MD</td>
<td>700.00 €</td>
<td>800.00 €</td>
<td>900.00 €</td>
</tr>
</tbody>
</table>

*Students/Residents/Trainee:* Proof of status is mandatory - In order to benefit from the special fee, a submission of your status confirmation (approval letter signed by the Head of Department or copy of your status ID) must be uploaded during the Online registration.

The registration fee covers access to all scientific sessions, coffees and lunch breaks during the congress and the certificate of attendance.

Registration desk opening hours

**Wednesday,** from 07:45 to 20:00
**Thursday,** from 08:00 to 18:10
**Friday,** from 08:00 to 18:10
**Saturday,** from 08:00 to 13:00

Name badges

The name badges will be distributed from the Registration Area. All participants are kindly requested to wear their name badges throughout the conference.
General information

Certificate of attendance
Certificates of attendance will be sent directly right after the conference to the email address provided.

Exhibition opening hours
The exhibition will be open on 19 – 22 June 2024 during the congress hours:

Wednesday, from 09:30 to 17:45
Thursday, from 08:30 to 18:10
Friday, from 08:30 to 18:10
Saturday, from 08:30 to 13:00

Important dates
Deadline for early registration:
April 1st, 2024

Social programme
The social programme and activities for the InSiGHT 2024 Biennial Meeting are listed below:

Welcome Reception
Date | Time: Wednesday, June 19th 2024
Location: Auditori AXA Convention Center

*All INSiGHT2024 participants are cordially invited to the Welcome Reception.

BCN Sunset InSiGHT Night - Dinner
Date | Time: Friday, June 21st | 20:00pm
Location: Terraza Miramar - Plaça de l'Armada, s/n, Montjuïc, 08038 Barcelona

*Ticket must have been purchased in advance.
General information

**Wireless internet access**
Username: INSIGHT2024  
Password: HOLA

**Social media**

*Conference website*
In the conference website you will find all the information about the event, such as: scientific programme, speakers, committees, registration, venue and accommodation.  
tactics/insight-2024

Follow us on @insightmeeting and tweet with the hashtag #InSiGHT2024.  
twitter/insightmeeting

**EACCME accreditation**

InSiGHT 2024 Biennial Meeting will request CME Accreditation.

European Accreditation Council for Continuing Medical Education (EACCME)  
An institution of U.E.M.S.

**Lunch and refreshments**

Lunch boxes are included in the participants’ registration fee.  
Coffee & tea will be available in the exhibition area during the breaks.

**Safety & security**

Please do not leave your bags or suitcases unattended at any time, whether inside or outside the session halls. Cloakroom will not be available in this occasion.
General information

Liability & insurance
By registering for the Congress and/or by participating in the exhibition joined to the Congress, participants and exhibitors agree that InSiGHT, the Organising Committee or the Congress Secretariat do not assume any responsibility for damage or injuries to persons or property during the Congress. Participants and exhibitors are advised to organize their own health, travel, and personal insurance.

Letter of invitation
Upon request, the Chairman of the Local Organising Committee will be pleased to send a personal letter of invitation to registered participants so as to enable participants to obtain visas for attending the Congress. These invitation letters cannot be considered as an offer of financial support by the organisers and will only be provided to registered participants once the payment has been received.

Eco-friendly & paperless
InSiGHT is a paperless, sustainable and environmentally friendly Conference encouraging the use of recyclable material.

Smoking
InSiGHT 2024 is a non-smoking congress.

Abstract book
Abstract book will be published online on the congress website.
The 10th Biennial Meeting of the International Society for Gastrointestinal Hereditary Tumours, has been assessed as COMPLIANT with the MedTech Europe Code of Ethical Business Practice by EthicalMedTech.
11th Biennial Meeting of the International Society for Gastrointestinal Hereditary Tumours
4 – 7 MARCH 2026 | SINGAPORE
RAID-CRC

Non-invasive faecal microbial test as a key tool to increase Colorectal Cancer screening efficiency by 12-15% \(^1\)

\(^1\) Malagón M, Oliver L, Ramis-Pujol S, Guardiola J, Balaguer F. Returning to endoscopy normality through the support of a new non-invasive faecal test based on microbial signatures. Digestive and Liver Disease. 2021; 53(12):1666-1668